A detailed history of Creative Planning transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Creative Planning holds 16,955 shares of VKTX stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,955
Previous 15,753 7.63%
Holding current value
$1.17 Million
Previous $835,000 28.5%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$49.84 - $70.47 $59,907 - $84,704
1,202 Added 7.63%
16,955 $1.07 Million
Q2 2024

Aug 15, 2024

BUY
$47.39 - $80.2 $72,222 - $122,224
1,524 Added 10.71%
15,753 $835,000
Q1 2024

May 10, 2024

BUY
$17.4 - $94.5 $247,584 - $1.34 Million
14,229 New
14,229 $1.17 Million
Q3 2023

Nov 16, 2023

SELL
$10.92 - $16.0 $44,761 - $65,584
-4,099 Reduced 73.21%
1,500 $16,000
Q2 2023

Jul 21, 2023

BUY
$14.84 - $24.79 $29,116 - $48,637
1,962 Added 53.95%
5,599 $90,000
Q1 2023

May 15, 2023

SELL
$8.08 - $17.33 $47,979 - $102,905
-5,938 Reduced 62.02%
3,637 $60,000
Q4 2022

Feb 10, 2023

BUY
$2.72 - $9.4 $26,044 - $90,005
9,575 New
9,575 $90,000
Q3 2020

Nov 05, 2020

SELL
$5.73 - $8.11 $131,635 - $186,311
-22,973 Closed
0 $0
Q2 2020

Jul 23, 2020

SELL
$4.35 - $8.08 $85,260 - $158,368
-19,600 Reduced 46.04%
22,973 $166,000
Q1 2020

May 05, 2020

BUY
$3.45 - $7.95 $10,350 - $23,850
3,000 Added 7.58%
42,573 $199,000
Q4 2019

Jan 30, 2020

SELL
$6.38 - $8.73 $32,538 - $44,523
-5,100 Reduced 11.42%
39,573 $317,000
Q3 2019

Nov 01, 2019

BUY
$6.55 - $8.6 $29,874 - $39,224
4,561 Added 11.37%
44,673 $307,000
Q2 2019

Jul 26, 2019

BUY
$7.67 - $10.63 $7,762 - $10,757
1,012 Added 2.59%
40,112 $333,000
Q1 2019

Apr 24, 2019

BUY
$7.58 - $9.94 $49,270 - $64,610
6,500 Added 19.94%
39,100 $389,000
Q4 2018

Feb 01, 2019

BUY
$7.16 - $16.21 $233,416 - $528,446
32,600 New
32,600 $249,000
Q2 2018

Jul 20, 2018

SELL
$3.88 - $12.74 $341,983 - $1.12 Million
-88,140 Closed
0 $0
Q1 2018

Apr 18, 2018

BUY
$4.11 - $6.93 $74,555 - $125,710
18,140 Added 25.91%
88,140 $385,000
Q4 2017

Jan 17, 2018

BUY
$1.74 - $4.34 $104,400 - $260,400
60,000 Added 600.0%
70,000 $284,000
Q3 2017

Oct 17, 2017

BUY
$0.94 - $1.91 $9,400 - $19,100
10,000
10,000 $19,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.28B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.